Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Expert Rev Clin Pharmacol
; 7(4): 443-50, 2014 Jul.
Article
em En
| MEDLINE
| ID: mdl-24742319
Seminal advances in the treatment of cancer have been achieved because of drug development in ovarian cancer; notably the developments of platinums and taxanes. However, no new drug has been FDA approved for ovarian cancer since 2006, and the approval of an antiangiogenic agent for ovarian cancer in the US has stalled. Predicting the next breakthrough is a high risk and highly expensive venture. One of the most promising prospects is folate-receptor (FR)-targeted therapy, given the high expression in FR ovarian cancer. We review the development of vintafolide (EC145), a folic acid-desacetylvinblastine conjugate, the predictive utility of a FR-targeted imaging agent, technetium-(99)m-etarfolatide (EC20), the challenges in proving survival advantage, and other approaches to exploiting FR as a target in ovarian cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Compostos Organoplatínicos
/
Neoplasias Ovarianas
/
Alcaloides de Vinca
/
Receptor 1 de Folato
/
Ácido Fólico
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article